 Home > Active Ingredient News > Drugs Articles > Top 20 R&D expenses of domestic pharmaceutical companies (first three quarters of 2022)

Top 20 R&D expenses of domestic pharmaceutical companies (first three quarters of 2022)

 Last Update: 2022-11-04
 Source: Internet
 Author: User

Tags

antabuse half life

tsp stage 1

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

As of the evening of October 30, the third quarterly report of A-share listed pharmaceutical companies has basically been disclosed (BeiGene disclosed on November 12); We have compiled the R&D expenses for the first three quarters, as shown in the following table:

A-share listed pharmaceutical company

Chart: Top 20 R&D expenses of A-share listed pharmaceutical companies in the first three quarters of 2022

Remarks: Pharmaceuticals, Biotechnology and Life Sciences for Healthcare by GICS Industry Classification

BeiGene ranked first, with R&D expenditure of 5.
016 billion yuan in the first half of this year, and is expected to remain the first in the first
three quarters.

At number one is BeiGene

Hengrui Pharmaceutical's R&D expenditure in the first three quarters of this year was 3.
498 billion yuan, a year-on-year decrease of 15.
56%.

On October 28, Hengrui Pharmaceutical released 2022 In the third quarter of the year, the company achieved revenue of 15.
945 billion yuan in the first three quarters, a year-on-year decrease of 21.
06%, and a net profit of 3.
051 billion yuan, a year-on-year decrease of 26.
46%.

2022 In the Q3 quarter of this year, Hengrui Pharmaceutical achieved revenue of 5.
717 billion yuan, an increase of 20.
38%
from the previous month.
The net profit attributable to the parent was 1.
054 billion yuan, up 19.
46% from the previous month, and the net profit of non-attributable parent was 10.
43 100 million yuan, up 25.
81%
month-on-month.
The company's performance was affected by the epidemic in the second quarter, and its performance in the third quarter improved
significantly from the previous quarter.

Hengrui Pharmaceutical's R&D expenditure in the first three quarters of this year was 3.
498 billion yuan, a year-on-year decrease of 15.
56%.

2022 In the Q3 quarter of this year, Hengrui Pharmaceutical achieved revenue of 5.
717 billion yuan, an increase of 20.
38%
from the previous month.
The net profit attributable to the parent was 1.
054 billion yuan, up 19.
46% from the previous month, and the net profit of non-attributable parent was 10.
43 100 million yuan, up 25.
81%
month-on-month.

Fosun Pharma: In the first three quarters of 2022, the Group's R&D investment totaled RMB3.
761 billion, a year-on-year increase of 19.
36%; Among them, R&D expenses were 28.
49 100 million yuan, an increase of 435 million yuan year-on-year 18.
02%
。 In the first three quarters, the operating income was 31.
610 billion yuan (+16.
87%), the net profit attributable to the parent was 2.
454 billion yuan (-31.
15%), and the non-net profit was 2.
859 billion yuan (+15.
51%)
.
2022 Year 7 In January, Fosun Pharma Industry, a holding subsidiary, reached a strategic cooperation with Real Biologics, in which the two parties jointly developed and exclusively commercialized azvudine by Fosun Pharma in the fields of
new coronavirus and HIV/AIDS treatment and prevention.

Fosun Pharma: 2022 Year 7 In January, Fosun Pharma Industry, a holding subsidiary, reached a strategic cooperation with Real Bio

The joint venture company Fosun Kite is based on Yescarta, a CAR-T cell therapy product introduced from Kite Pharma The third indication for the first product that underwent technology transfer and localized production in China, iqaida (Aquilenca injection) (for the treatment of adult Big B who do not respond to first-line immunochemotherapy or relapse within 12 months after first-line immunochemotherapy Cellular lymphoma, r/r LBCL) was accepted in October 2022 and included in the list of
priority varieties.

CAR-T cell therapy products

Junshi Biologics: Revenue in the first three quarters of 2022 was RMB1.
218 billion, down 55% year-on-year; R&D expenditure was RMB1.
636 billion, up 15%
year-on-year.
Among them, the company's operating income mainly comes from the sales revenue
brought by the commercialization of trepilimab injection (Tuoyi) in the domestic market.
2022 In the third quarter of this year, Tuoyi achieved sales revenue of approximately RMB 2.
18 (Tuoyi sales revenue in the first half of 2022 totaled 298 million yuan, of which the first quarter revenue was about 110 million yuan, the second quarter revenue was about 190 million yuan, and the annual sales revenue in 2021 was 412 million yuan).

Junshi Biologics: R&D expenditure was RMB1.
636 billion, a year-on-year increase of 15% in 2022 In the third quarter of this year, Tuoyi achieved sales revenue of approximately RMB 2.
18 billion,

Health Yuan: R&D expenditure in the first three quarters was 1.
233 billion yuan, an increase of 28.
51%.

The operating income was 13.
012 billion yuan (+9.
04%), the net profit attributable to the parent was 1.
127 billion yuan (+11.
69%), and the non-net profit was 1.
116 billion yuan (+21.
40%)
.

Health Element:

WuXi AppTec: R&D expenditure in the first three quarters was 1.
089 billion yuan, a significant increase of 69.
09%, which is a company
with high R&D expenditure of domestic CXO.
In the first three quarters, the operating income was 28.
395 billion yuan (+71.
87%), the net profit attributable to the parent was 7.
378 billion yuan (+107.
12%), and the non-net profit was 6.
232 billion yuan (+100.
64%)
.

WuXi AppTec:

Kelun Pharmaceutical: R&D expenditure in the first three quarters of this year was 1.
204 billion yuan, a year-on-year increase of 1.
27%.

In the first three quarters, the operating income was 13.
858 billion yuan (+9.
24%), the net profit attributable to the parent was 1.
411 billion yuan (+66.
33%), and the non-net profit was 1.
377 billion yuan (+71.
42%)
.
In 2016, the subsidiary Kolumpatai was established, the company laid out biotechnology drug research and development and internationalization strategy, as of 2022H1, 14 innovative drug projects have entered the clinical development stage, spanning monoclonal antibodies, bispecific antibodies, ADC and other fields, and the indications cover major diseases such
as malignant tumors, liver diseases, autoimmunity, anesthesia and analgesia, uremia itching, etc.
Up to now, 2 ADCs of Kelun Pharmaceutical have reached cooperation authorization with Merck for overseas rights and global rights respectively, and the company's R&D strength has been verified
.

Kelun Pharmaceutical: Up to now, two ADCs of Kelun Pharmaceutical have reached cooperation authorization with Merck for overseas rights and global rights respectively, and the company's R&D strength has been verified
.

From the perspective of A-share listed pharmaceutical companies, the top 20 R&D expenses in the first three quarters basically exceeded 600 million yuan, and most of them maintained double-digit growth
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.